
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corporation demonstrates a positive outlook due to its potential advancements with Furoscix, particularly if the auto-injector receives approval, which could significantly enhance the company's revenue stream. The possibility of label expansion for the Tyvaso DPI version is viewed as a fundamental driver for MannKind’s stock, especially amid ongoing developments in treatments for conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Arterial Hypertension (PAH). Additionally, the successful deal with SCPH is crucial as it reinforces market confidence in MannKind's capital allocation strategy, complementing anticipated peak sales growth for Furoscix despite its niche market characteristics.
Bears say
MannKind Corporation's stock has experienced a significant decline, attributed to competitive pressures following SQ Innovation's approval of a competing product priced at approximately 50% lower than Furoscix. Additionally, expectations for Afrezza's sales, projected at $127 million by 2030, may prove overly optimistic, considering the inherent risks and uncertainties surrounding the pediatric market opportunity and pipeline projects MNKD-101 and MNKD-201, with low probability of success. Overall, the impact of market reactions to pricing uncertainties and competitive products, alongside cautious sales forecasts, raises concerns regarding MannKind's future financial stability and growth potential.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares